Abstracts tagged "Lupus nephritis"

Abstract Number: 0812 • ACR Convergence 2024
A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares
Abhimanyu Amarnani¹, Cristobal Rivera-Martinez¹, Marc Scherlinger², Doua Azzouz¹, Andy Lee¹, Kate Trujillo¹, MacIntosh Cornwell¹, Tyler Weinstein¹, Tatiana Borja³, Bharati Matta⁴, Sharon Chung⁵, Laura Cooney⁶, Uzair Chaudhary¹, Steven Medvedovsky¹, Peter Izmirly¹, Jill Buyon¹, Patrick Blanco⁷, Betsy Barnes⁸, Bhama Ramkhelawon¹, Kelly Ruggles⁹ and Gregg Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²Strasbourg University Hospital, Strasbourg, France, ³Feinstein Institutes for Medical Research, New York, NY, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ⁵University of California, San Francisco and Immune Tolerance Network, San Francsico, ⁶University of Michigan and Immune Tolerance Network, Ann Arbor, MI, ⁷UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁸Feinstein Institutes for Medical Science, Manhasset, NY, ⁹NYU Grossman School of Medicine, Brooklyn, NY
Background/Purpose: SLE is a leading cause of premature death, often from severe complications including lupus nephritis (LN), especially in disadvantaged groups. Despite advances in treatment,…
Abstract Number: 1538 • ACR Convergence 2024
Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Meenakshi Jolly¹, Matt Truman², Ronald Flauto³ and Kathryn Dao⁴, ¹Rush University, Chicago, IL, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals, Rockville, MD, ⁴Rheum101, Rockville, MD
Background/Purpose: Voclosporin used in addition to Mycophenolate Mofetil and low dose oral steroids in patients with active Lupus Nephritis (LN) was found to be superior…
Abstract Number: 1873 • ACR Convergence 2024
Race/Ethnicity and Household Income at the County Level Interacts with the Association of Urbanicity and Lupus Nephritis Mortality
Snehin Rajkumar¹, Eric Yen² and Ram Singh³, ¹UCLA David Geffen School of Medicine, Irvine, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The reasons underlying substantial variation in lupus nephritis (LN) deaths by race/ethnicity remain largely unknown. There are no large population-based studies focused on the…
Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
April Jorge¹, Aakash Patel¹, Baijun Zhou², Yuqing Zhang³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…
Abstract Number: 0085 • ACR Convergence 2024
A Novel, Potent and Selective TLR7/8 Small Molecule Inhibitor Blocks TLR7/8 Pathway in the Presence of HCQ and Demonstrates Robust Preclinical Efficacy in Lupus Models
Ching Shang¹, Angie Hammond², Yuanjiang Yu¹, Bing Xia¹, Yew Ann Leong¹, Emily Chung¹, zhiyu Huang¹, Paqui Gonzalez Traves³, Wesley Minto¹, Sunish Mohanan¹, Hailing Zong¹, Gundula Min-oo¹, Stephen Ammann⁴, Eda Canales⁵ and Natasha Crellin³, ¹Gilead Sciences, Foster City, CA, ²Gilead Sciences, Inc., Seattle, WA, ³Gilead, Foster City, CA, ⁴Gilead Sciences, Foster City, ⁵Gilead Sciences, San Mateo, CA
Background/Purpose: Toll-like receptor 7, 8 and 9 (TLR7/8/9) are endosomal nucleic acid sensors that when aberrantly activated, induce Type I interferon (IFNα), proinflammatory cytokines, immune…
Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0832 • ACR Convergence 2024
Spatial Transcriptomic Assessment of Histologically Damaged and Unaffected Glomeruli in Class III Pediatric Lupus Nephritis Reveals Distinct Transcriptional Programs
Sarah McCuaig¹, Portia Kreiger¹ and Edward Behrens², ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, West Chester, PA
Background/Purpose: Lupus nephritis (LN) occurs in over 50% of patients with pediatric systemic lupus erythematosus (pSLE) and results in significant morbidity due to suboptimal kidney…
Abstract Number: 1545 • ACR Convergence 2024
Rates of Sustained Complete Renal Response with Long-term Use of Voclosporin in AURORA 2
Ernie Yap¹, Matt Truman², Cynthia Auguste¹, Vanessa Birardi³ and Greg Keenan¹, ¹Aurinia Pharmaceuticals Inc., Edmonton, Canada, ²Aurinia Pharmaceuticals, Victoria, BC, Canada, ³Aurinia Pharmaceuticals Inc., Rockville, MD
Background/Purpose: Unlike in many other disease states, there is no accepted definition for clinical response in lupus nephritis (LN). The Phase 3 AURORA 1 study…
Abstract Number: 1876 • ACR Convergence 2024
Automated Case Identification of Patients with End-Stage Renal Disease and Systemic Lupus Erythematosus Using Machine Learning
Mario Felix¹ and Lais Osmani², ¹Yale, Hamden, CT, ²Yale, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease, with 4-28% of patients developing End-Stage Renal Disease (ESRD). Accurate identification of these patients is…
Abstract Number: 2579 • ACR Convergence 2024
Risk of End-Stage Renal Disease Among Patients with Lupus Nephritis on GLP-1 Receptor Agonists: A Retrospective Cohort Study
Anna-Kay Palmer¹ and Irene Tan², ¹Jefferson Einstein Hospital, Philadelphia, PA, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic inflammatory autoimmune disease which frequently affects the kidneys. Lupus nephritis (LN) is associated with increased morbidity and…
Abstract Number: 0090 • ACR Convergence 2024
Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus
Minjung Kim¹, Anthony Marinov², Haylee Cosgrove³, Xiaoyan Gong³, Mark Shlomchik³ and Jeremy Tilstra³, ¹University of Illinois College of Medicine at Chicago, Chicago, IL, ²University of Pittsburgh, Homestead, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
Abstract Number: 0650 • ACR Convergence 2024
Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis
Yevgeniya Gartshteyn¹, Laura Geraldino², Shuwei Wang³, Vivette D'Agati¹ and Robert Winchester¹, ¹Columbia University Irving School of Medicine, New York, NY, ²Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, ³Rutgers New Jersey Medical School, Newark, NJ
Background/Purpose: Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 1546 • ACR Convergence 2024
Characteristics and Treatment Patterns of Patients with Lupus Nephritis: A Retrospective Claims Database Study in the USA
Anisha M. Patel¹, Carmen Ng¹, Lisa Lindsay¹, Zhiyu Xia², William F. Pendergraft III³ and Maria Dall'Era⁴, ¹Genentech, Inc., South San Francisco, ²Genentech, Inc., Sou, ³Genentech, Inc., Chapel Hill, NC, ⁴UCSF, Corte Madera, CA
Background/Purpose: Accounting for the integration of new immunosuppressive treatment options (belimumab and voclosporin) since 2021, we aimed to describe real-world treatment patterns in patients with…
Abstract Number: 2159 • ACR Convergence 2024
Reaching Those in Need: Understanding the Reach of a Digital Program for Lupus Self-Management Education
Katherine Carpenter¹, Melissa French², Sara Johnson³, Janet Johnson³, Ashley Holden⁴, Joy Buie¹, Melicent Miller¹ and Mary Crimmings¹, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Alexandria, VA, ³ProChange Behavior Solutions, South Kingstown, RI, ⁴Lupus Foundation of America, Bossier City, LA

Background/Purpose: As part of a 5-year cooperative agreement with the Centers for Disease Control and Prevention, The Lupus Foundation of America (LFA) has implemented the…

« Previous Page
1
…
3
4
5
6
7
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].